ImmunityBio (IBRX) Net Cash Flow (QoQ) (2014 - 2026)
Powered by 
Analysis
ImmunityBio (IBRX) Net Cash Flow (QoQ) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.45 Bn | 8.09 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -210.82% |
| Mar 31, 2026 | 315.47% |
| Dec 31, 2025 | 136.63% |
| Sep 30, 2025 | -199.83% |
| Jun 30, 2025 | 192.95% |
| Mar 31, 2025 | -361.74% |
| Dec 31, 2024 | 274.22% |
| Sep 30, 2024 | -516.68% |
| Jun 30, 2024 | 97.78% |
| Mar 31, 2024 | -251.26% |
| Dec 31, 2023 | -34.92% |
| Sep 30, 2023 | 399.05% |
| Jun 30, 2023 | -182.69% |
| Mar 31, 2023 | -5,086.21% |
| Dec 31, 2022 | -99.24% |
| Sep 30, 2022 | 66.18% |
| Jun 30, 2022 | 117.58% |
| Mar 31, 2022 | -224.06% |
| Dec 31, 2021 | 698.17% |
| Sep 30, 2021 | -149.65% |